AI assistant
MAXCYTE, INC. Director's Dealing 2024
10520_sha_2024-11-06_758cb515-9cd3-431c-8832-5ee914ad35fe.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 2188L
MaxCyte, Inc.
06 November 2024
MaxCyte, Inc.
("MaxCyte" or the "Company")
Exercise of options and PDMR dealing
ROCKVILLE, MD, November 6, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 5 November 2024, as per a filing lodged with the U.S. Securities and Exchange Commission, Stanley Erck, a Non-Executive Director of the Company, exercised options over 47,689 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 47,689 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by Stanley Erck at a price range between $3.610 and $3.755 per Common Stock ("Sale"). The sold shares represent approximately 8.04% of Stanley Erck's total equity and option holdings in the Company's stock capital, respectively.
Following the Exercise and Sale, Stanley Erck holds 247,751 shares of Common Stock representing 0.2% of the issued stock capital of the Company. Following the Exercise, Stanley Erck holds a further 276,501 options over Common Stock and 21,367 restricted stock units.
The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Stanley Erck on 12 March 2024 relating solely to the sale of shares acquired from exercise of options that expire on 11 November 2024.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Stanley Erck | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-Executive Director | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | MaxCyte, Inc. | |||
| b) | LEI | 54930053YHXULRFCU991 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Common Stock of $0.01 each | |||
| Identification code | US57777K1060 | ||||
| b) | Nature of the transaction | Exercise of Options over common stock | |||
| c) | Price(s) and volume(s) | ||||
| Exercise Price(s) | Volume(s) | ||||
| $0.040 | 47,689 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | 47,689 | ||||
| - Price | $0.040 | ||||
| e) | Date of the transaction | 1 November 2024 | |||
| f) | Place of the transaction | US Stock Exchange, Nasdaq | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Stanley Erck | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-Executive Director | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | MaxCyte, Inc. | |||
| b) | LEI | 54930053YHXULRFCU991 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Common Stock of $0.01 each | |||
| Identification code | US57777K1060 | ||||
| b) | Nature of the transaction | Sale of common stock | |||
| c) | Price(s) and volume(s) | ||||
| Exercise Price(s) | Volume(s) | ||||
| $3.6100 | 100 | ||||
| $3.6400 | 100 | ||||
| $3.6450 | 200 | ||||
| $3.6500 | 1500 | ||||
| $3.6550 | 1370 | ||||
| $3.6600 | 500 | ||||
| $3.6650 | 290 | ||||
| $3.6700 | 774 | ||||
| $3.6750 | 780 | ||||
| $3.6800 | 550 | ||||
| $3.6850 | 1150 | ||||
| $3.6900 | 650 | ||||
| $3.6950 | 3312 | ||||
| $3.7000 | 5910 | ||||
| $3.7050 | 1626 | ||||
| $3.7100 | 888 | ||||
| $3.7150 | 1375 | ||||
| $3.7200 | 5460 | ||||
| $3.7250 | 330 | ||||
| $3.7300 | 4667 | ||||
| $3.7350 | 675 | ||||
| $3.7400 | 6010 | ||||
| $3.7450 | 795 | ||||
| $3.7500 | 7297 | ||||
| $3.7550 | 1380 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | 47,689 | ||||
| - Price | $3.7157 | ||||
| e) | Date of the transaction | 1 November 2024 | |||
| f) | Place of the transaction | US Stock Exchange, Nasdaq |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEADFKELELFFA